InpharmD vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI drug information platform with clinical pharmacist review for healthcare providers; $6.5M seed from 645 Ventures and YC competing with UpToDate for complex drug interaction and dosing guidance.
About
InpharmD is an Atlanta-based healthcare technology company providing AI-assisted drug information and clinical pharmacist intelligence to healthcare providers — enabling physicians, nurses, and clinical staff to get evidence-based answers to complex drug questions (drug interactions, off-label use guidance, dosing in special populations, emerging therapies) through an AI platform that combines clinical pharmacist review with database-backed pharmaceutical intelligence. Founded in 2018 and a Y Combinator W21 graduate, InpharmD raised $6.63 million total including a $6.5 million seed round in December 2023 led by 645 Ventures with participation from Qlarant Capital and Atlanta Ventures.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.